QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in innovative in vitro diagnostic technologies for point-of-care settings, clinical labs, and transfusion medicine, will report its financial results for the third quarter of 2024, ending September 29, 2024. The results will be released after market close on Thursday, November 7, 2024.
Following the announcement, QuidelOrtho will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the financial outcomes. Interested participants can join the call via the “Events & Presentations” section on the Company’s Investor Relations page at quidelortho.com. Presentation materials will also be available during the call. For those unable to access the webcast, the call can be joined by phone at 833-470-1428 (domestic) or +1 929-526-1599 (international), using Conference ID number 117739.
A replay of the conference call will be accessible shortly after the event on the Company’s Investor Relations website.
QuidelOrtho is committed to advancing diagnostics for a healthier future. For more information, visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook, and X.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a leading provider of in vitro diagnostics, delivering intelligent solutions that turn data into actionable insights. With expertise in immunoassay, molecular testing, clinical chemistry, and transfusion medicine, QuidelOrtho offers fast, accurate diagnostics across various healthcare settings. The company collaborates with healthcare partners worldwide to pave the way for innovative diagnostic solutions that enhance patient care.
